Randomized trial of relevance of time-of-day of immunochemotherapy for progression-free and overall survival in patients with non-small cell lung cancer. Data are n (%). This is an ASCO Meeting ...

The event, hosted by LiveLung, offered attendees a chance to share their journeys and hear from experts, including Dr. Lauren ...

Veronica shares the story of her 29-year-old son who fought lung cancer, and how it has inspired her advocacy.

LiveLung, a 501(c)(3) nonprofit organization dedicated to supporting lung cancer patients, survivors, and their care partners, created the inaugural Lung Cancer Advocates at ASCO Program, co-lead ...

She said not only was lung cancer Australia's deadliest cancer, killing almost 9,000 people a year, but the five-year survival rate for lung cancer was just 26 per cent, compared to breast cancer ...

“This is my CT scan that I had in 2020, and you can see this fuzzy area up in the right side of my lung. That was the tumor when it was quite small,” said Maryann Stein, a lung cancer survivor.

NEW YORK, June 10, 2025 /PRNewswire/ -- The Lung Cancer Research Foundation (LCRF) is pleased to announce the expansion of its Research Advocates. This select group of volunteers are patients ...

Neoadjuvant nivolumab plus chemotherapy significantly improved pathological complete response and event-free survival in patients with resectable non–small-cell lung cancer (NSCLC) in a phase 3 ...

Swarner led a discussion with lung cancer survivor Maggie McCloskey, patient advocate and podcast host Dave Bjork and J&J’s president of solid tumor, U.S. oncology, Biljana Naumovic, M.D.